-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology Luminex Platform: A New Driving Force for Drug Development
Author:
InnoModels
Release time:
2024-06-28
In the vast world of pharmaceutical R&D, technological innovation is the core driving force for scientific progress. By virtue of its Luminex platform, InnoModels Biotechnology has demonstrated significant advantages in the field of drug discovery and development, providing strong technical support for new drug discovery and development. In this article, we will introduce the advantages of Luminex platform and discuss its important role in drug discovery.
Technical advantages of Luminex platform:
1. High-throughput detection capability: With its unique multi-detection technology, the Luminex platform is capable of detecting multiple biomarkers at the same time, realizing high-throughput sample processing. This advantage is especially critical in drug discovery and development, as it accelerates the drug screening process and improves R&D efficiency.
2. High sensitivity: The Luminex platform is extremely sensitive and can accurately measure biomarkers at very low concentrations. This is important for studying the mechanism of action of drugs in organisms, evaluating drug efficacy, and monitoring adverse drug reactions.
3. Low sample requirements: The Luminex platform requires a very small sample size to perform multiple assays, which is a huge advantage for drug discovery and development that values sample resources. At the same time, it also reduces the difficulty and cost of sample collection and improves the feasibility of experiments.
4. High degree of automation: Luminex platform supports automated operation, which can greatly reduce manual operation, lower experimental errors and improve data accuracy. In addition, automated operation can save researchers' time and energy, enabling them to focus more on experimental design and data analysis.

Application of Luminex platform in drug discovery:
1. Drug screening: The high-throughput detection capability of the Luminex platform makes it an ideal tool for drug screening. Researchers can utilize the platform to simultaneously detect the effects of multiple drugs on biomarkers, thereby screening for potentially efficacious drugs.
2. Efficacy assessment: The Luminex platform can accurately measure the effects of drugs in living organisms, including the effects of drugs on biomarkers and changes in cell function. These data are important for evaluating the efficacy and safety of drugs.
3. Drug monitoring: The Luminex platform can also be used to monitor the metabolism and excretion processes of drugs in organisms, as well as the potential adverse effects of drugs on organisms. This information is of great value in developing a rational medication regimen and ensuring patient safety.
Conclusion:
With its advantages of high throughput detection capability, high sensitivity, low sample requirement and high degree of automation, the Luminex platform of InnoModels Biotechnology has shown great potential in the field of drug discovery and development. The platform not only accelerates the drug screening process and improves R&D efficiency, but also provides accurate and reliable data support for drug development. In the future, with the continuous advancement of technology and the expansion of applications, the Luminex platform will play an even more important role in drug discovery and development, and make greater contributions to human health.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd